View Financial HealthAptevo Therapeutics 配当と自社株買い配当金 基準チェック /06Aptevo Therapeutics配当金を支払った記録がありません。主要情報n/a配当利回り-662.1%バイバック利回り総株主利回り-662.1%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesAptevo Therapeutics Inc Announces New Interim Data For Mipletamig In Combination With Venetoclax And AzacitidineMar 14New major risk - Share price stability Mar 10Aptevo Announces CEO ChangesFeb 04+ 1 more updateNew major risk - Market cap size Dec 31New major risk - Share price stability Nov 28Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $11.802524 million.Nov 08New major risk - Market cap size Aug 03Aptevo Therapeutics Inc., Annual General Meeting, Jul 24, 2025Jun 24Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.Jun 17Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Stockholders' Equity RequirementMay 23New major risk - Negative shareholders equity May 17Aptevo Therapeutics Inc. has withdrawn its Follow-on Equity Offering in the amount of $17.5 million.May 13Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $2.959952 million.Apr 28Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2.003288 million.Apr 23Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $1.99864 million.Apr 22Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $2.100005 million.Apr 04New minor risk - Profitability Dec 19Aptevo Therapeutics Inc. Announces 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline Aml TrialDec 13Aptevo Therapeutics Inc. Announces Bispecific Antibody, Apvo442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side EffectsDec 05Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split as Part of Nasdaq Compliance PlanDec 02Aptevo Therapeutics Expands on the Potential of MipletamigNov 21Aptevo Therapeutics (Aptevo) and Alligator Bioscience AB Announce Preliminary Data from Its Phase 1 Trial Evaluating the First-In-Class Bispecific Antibody, ALG.APV-527Nov 12Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2.999493 million.Sep 19Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor StudySep 16Alligator Bioscience AB (publ) and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV- 527 Monotherapy in Multiple Solid Tumor Types At ESMO Congress 2024Sep 14Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.Aug 31Aptevo Therapeutics Inc. Announces That Phase 1B/2 "Rainier" Frontline Acute Myeloid Leukemia (Aml) Trial InitiatedAug 14Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Nasdaq Listing Rule 5550(a)(2)Jul 02+ 1 more updateAptevo Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $5 million.Jun 15Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2 million.May 09Aptevo Therapeutics Inc., Annual General Meeting, Jun 07, 2024Apr 24Price target increased by 49% to US$671 Apr 23Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $4.589753 million.Apr 16Aptevo Therapeutics Inc. Provides Pipeline UpdateApr 11New major risk - Share price stability Apr 10Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.Mar 21Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4Mar 07Aptevo Therapeutics Announces 1-For 44 Reverse Stock Split as Part of Nasdaq Compliance PlanMar 05New major risk - Revenue and earnings growth Nov 15Aptevo Therapeutics Receives Non-Compliance Letter from the Staff of the Nasdaq Stock MarketSep 16New minor risk - Profitability Aug 11Price target decreased by 33% to US$12.00 Aug 10Aptevo Therapeutics Inc. Announces Positive Duration of Remission Data from Phase 1B Expansion Trial Evaluating the Bispecific APVO436 for AMLJul 21New major risk - Shareholder dilution Jul 08New major risk - Market cap size Jun 25Full year 2022 earnings: EPS exceeds analyst expectations Mar 31Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical TrialFeb 15Aptevo Therapeutics Inc. Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid TumorsJan 10Investor sentiment improved over the past week Dec 12Consensus forecasts updated Nov 17Price target decreased to US$18.00 Nov 16Insufficient new directors Nov 16Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.45 loss in 3Q 2021) Nov 11Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy Sep 19Investor sentiment deteriorated over the past week Aug 19Consensus forecasts updated Aug 18Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 12Consensus revenue estimates fall by 15% May 19Price target decreased to US$52.50 Apr 27Insufficient new directors Apr 27Third quarter 2021 earnings released: US$1.45 loss per share (vs US$2.15 loss in 3Q 2020) Nov 13Price target decreased to US$59.50 Oct 16Insufficient new directors Oct 16決済の安定と成長配当データの取得安定した配当: APVOの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: APVOの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Aptevo Therapeutics 配当利回り対市場APVO 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (APVO)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.6%アナリスト予想 (APVO) (最長3年)n/a注目すべき配当: APVOは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: APVOは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: APVOの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: APVOが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/04 20:12終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aptevo Therapeutics Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Wangzhi LiLadenburg Thalmann & CompanyEdward TenthoffPiper Sandler CompaniesJonathan AschoffRoth Capital Partners
Aptevo Therapeutics Inc Announces New Interim Data For Mipletamig In Combination With Venetoclax And AzacitidineMar 14
Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $11.802524 million.Nov 08
Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Stockholders' Equity RequirementMay 23
Aptevo Therapeutics Inc. has withdrawn its Follow-on Equity Offering in the amount of $17.5 million.May 13
Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $2.959952 million.Apr 28
Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2.003288 million.Apr 23
Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $1.99864 million.Apr 22
Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $2.100005 million.Apr 04
Aptevo Therapeutics Inc. Announces 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline Aml TrialDec 13
Aptevo Therapeutics Inc. Announces Bispecific Antibody, Apvo442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side EffectsDec 05
Aptevo Therapeutics (Aptevo) and Alligator Bioscience AB Announce Preliminary Data from Its Phase 1 Trial Evaluating the First-In-Class Bispecific Antibody, ALG.APV-527Nov 12
Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2.999493 million.Sep 19
Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor StudySep 16
Alligator Bioscience AB (publ) and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV- 527 Monotherapy in Multiple Solid Tumor Types At ESMO Congress 2024Sep 14
Aptevo Therapeutics Inc. Announces That Phase 1B/2 "Rainier" Frontline Acute Myeloid Leukemia (Aml) Trial InitiatedAug 14
Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Nasdaq Listing Rule 5550(a)(2)Jul 02+ 1 more update
Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2 million.May 09
Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $4.589753 million.Apr 16
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4Mar 07
Aptevo Therapeutics Inc. Announces Positive Duration of Remission Data from Phase 1B Expansion Trial Evaluating the Bispecific APVO436 for AMLJul 21
Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical TrialFeb 15
Aptevo Therapeutics Inc. Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid TumorsJan 10